Congratulations to the NIDA labs who participated and received awards in the 2023 NIH Green Labs Program! Molecular Neuropsychiatry Section, Adjei, Nasser – Gold Translational Analytical Core, Kryszak, Lindsay – Silver Neuronal Circuits and Behavior Section, Sarsfield, Sarah – Silver Integrative Neuroscience Research Branch, Neuronal Networks Section, Barbano, Flavia – Bronze Molecular Targets and Medications… [Read More]
Hot Off the Press
µ-Opioid receptor antagonism facilitates the anxiolytic-like effect of oxytocin in mice
Hot Off the Press – March 26, 2024 Published in Translational Psychiatry by Khalin Nisbett, Leandro Vendruscolo and George Koob from the NIDA IRP Stress & Addiction Neuroscience Unit and Neurobiology of Addiction Section. Summary Nisbett et al. discovered that the anxiolytic-like (anxiety-reducing) effect of oxytocin can be modulated by the endogenous opioid system. We… [Read More]
Reviews To Read
Modeling methamphetamine use disorder and relapse in animals: Short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain
Reviews To Read – January 2024. Published in Neuroscience & Biobehavioral Reviews by Khalid Elhadi, Atul P. Daiwile, and Jean Lud Cadet of the NIDA IRP Molecular Neuropsychiatry Research Section. Methamphetamine use disorder (MUD) is very widespread in the world because methamphetamine is easy to make and cheap to buy. Heavy users usually take the drug… [Read More]
Featured Papers
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone
Featured Paper of the Month – June 2024
Published in Molecular Psychiatry by Marjorie Levinstein and Michael Michaelides, et al. of the NIDA IRP Biobehavioral Imaging and Molecular Neuropsychopharmacology Section.
In this article we performed an in depth in vivo, in vitro, and in silico analysis of (R,S)-methadone and its enantiomers. (S)-methadone is currently in phase III trials as an antidepressant and is frequently referred to as an N-methyl-D-aspartate receptor (NMDAR) antagonist, like ketamine. Here we show that (S)-methadone, like (R)-methadone and (R,S)-methadone is an agonist at the mu opioid receptor (MOR) and does not bind to NMDARs at physiologically relevant concentrations.
